ENDRA Life Sciences reports FY2025 net loss $7.0M; initiates strategic alternatives review

ENDRA Life Sciences Inc.

Net loss for Q4 2025 $3.2M vs $4.2M YoY; full year net loss $7.0M vs $11.5M in 2024.
Operating expenses fell to $5.8M in 2025 from $10.8M in 2024.
Cash and cash equivalents $762k as of Dec 31, 2025; $2.0M in digital asset treasury.
Board initiated evaluation of strategic alternatives on March 25, 2026; no timetable set.
TAEUS Liver feasibility study showed r=0.89 correlation with MRI-PDFF for liver fat.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.

Period: the quarter and year ended December 31, 2025
Net income: net loss of $3.2 million
Result: reported results

Exact text from the filing

in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-037497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.